Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine are part of an international team of scientists who identified mechanisms by which some multiple myelomas become resistant to initially effective T-cell therapies.
Data from the phase Ib/II OrigAMI-4 study found that first-line treatment with investigational subcutaneous amivantamab and hyaluronidase-lpuj in combination with a PD-1 inhibitor delivered clinically meaningful and durable antitumor activity in patients with head and neck squamous cell carcinoma that is recurrent or metastatic, PD-L1-positive, and HPV-unrelated.
